e-learning
resources
Stockholm 2002
Monday 16.09.2002
Cystic fibrosis: problem infections and new monitoring techniques
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
DNA fingerprinting of
Pseudomonas aeruginosa (Pa)
in cystic fibrosis patients: risk assessment of cross-colonisation in a CF revalidation centre
F. M. De Baets, S. Van Daele, P. Schelstraete, M. Vaneechoutte, G. Claeys, A. S. Moring, H. Franckx (Gent, De Haan, Belgium)
Source:
Annual Congress 2002 - Cystic fibrosis: problem infections and new monitoring techniques
Session:
Cystic fibrosis: problem infections and new monitoring techniques
Session type:
Oral Presentation
Number:
1366
Disease area:
Paediatric lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. M. De Baets, S. Van Daele, P. Schelstraete, M. Vaneechoutte, G. Claeys, A. S. Moring, H. Franckx (Gent, De Haan, Belgium). DNA fingerprinting of
Pseudomonas aeruginosa (Pa)
in cystic fibrosis patients: risk assessment of cross-colonisation in a CF revalidation centre. Eur Respir J 2002; 20: Suppl. 38, 1366
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
DNA fingerprinting of pseudomonas aeruginosa in cystic fibrosis patients: risk assessment of cross-infection in a CF centre
Source: Eur Respir J 2002; 20: Suppl. 38, 208s
Year: 2002
Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients
Source: Eur Respir J 2006 Oct 01;28(4):740-747
Year: 2006
Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=105
Year: 2006
Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients
Source: Eur Respir J 2008; 31: 822-829
Year: 2008
Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre
Source: Eur Respir J 2006; 27: 937-943
Year: 2006
Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre
Source: Eur Respir J 2005; 25: 474-481
Year: 2005
Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres
Source: Eur Respir J 2013; 41: 1091-1100
Year: 2013
Detection of Pseudomonas aeruginosa infection in cystic fibrosis patients by eNose technology
Source: International Congress 2018 – Latest developments in cystic fibrosis
Year: 2018
Achromobacter xylosoxidans
strains with shared genotype among patients attending a cystic fibrosis (CF) rehabilitation centre
Source: Eur Respir J 2005; 26: Suppl. 49, 596s
Year: 2005
Pseudomonas aeruginosa transmission is infrequent in New Zealand cystic fibrosis clinics
Source: Eur Respir J 2008; 32: 1583-1590
Year: 2008
Variability of ß-lactamase resistance Pseudomonas aeruginosa genes infecting patients with cystic fibrosis
Source: Virtual Congress 2021 – Back to infection basics
Year: 2021
Achromobacter (A.) xylosoxidans
in cystic fibrosis: prevalence and clinical relevance
Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Year: 2005
Omics-based tracking of
Pseudomonas aeruginosa
persistence in “eradicated” cystic fibrosis patients
Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020
Year: 2021
Antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis – clinical application
Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research
Year: 2018
Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis
Source: Eur Respir J 2004; 24 : 631-637
Year: 2004
Molecular genetic characteristics of Pseudomonas aeruginosa strains isolated from children with cystic fibrosis in Moscow.
Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects
Year: 2021
Detection of antibodies against Pseudomonas aeruginosa in the sputum of cystic fibrosis patients: A pilot study
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new basic and clinical physiology research
Year: 2012
Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa
Source: Eur Respir J 2003; 22: 503-506
Year: 2003
Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis
Source: Eur Respir J 2005; 26: 651-656
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept